Under our philosophy, "Beyond the bound of common sense, we conscientiously turn Creative Vision into Reality with ethos of Patient First", we provide future-generation technologies and services to the public, and aim for "benefit of people's health and contribution to the improvement of Quality of Life for Patient" as our mission. In the light of our philosophy and our mission, MEDINET launched "Immuno-Cell therapy Total Support Service", which is our core business at present. "Immuno-Cell therapy Total Support Service" is a comprehensive service that includes the technologies, know-how, equipments and faculties, materials, cell-engineers, IT systems to enable medical institutions to conduct immuno-cell therapy to the patients with cancers.
In fiscal year ending September 2009 ("FY2008"), MEDINET laid out its goal for turning into black in its financial statement, and has achieved such goal of balance in surplus. Actual results were net sales of JPY 2, 900 million, operating profit of JPY 293 million, and ordinary profit of JPY 323 million for the FY2008.
MEDINET carried out intensive marketing activities for medical doctors, healthcare professionals, and patients to improve awareness of Immuno-Cell Therapy as an option of cancer treatment. These marketing activities successfully resulted to support increase in the number of Allied Medical Institutions with MEDINET's Contracted Medical Institutions so as to increase in the number of cell-processings for the FY2008.
MEDINET has been continuously striving for commercialization of new and more effective Immuno-cell Therapy technology to the public by engaging basic research and clinical development. As our R&D activities for FY 2008, we had several opportunities to publish academic papers in distinguished journals and to present results of clinical studies/basic study to academia. Main topics of our results are as followed;-
| 1) |
We presented the result of a collaborative basic study against malignant glioma with Osaka National Hospital, a National Hospital Organization, at the 30th Annual Meeting of Japanese Research Society of Surgical Cancer Immunology, on May 2009. This basic research was carried out by using a novel Dendritic Cell ("DC") vaccine therapy, and showed the result of higher antigen uptake ability and CTL induction ability of DCs than conventional co-cultured DCs. By this presentation, we received the "Encouragement Prize" from Japanese Research Society of Surgical Cancer Immunology. |
| 2) |
The paper, titled "A combination therapy of gemcitabine with immunotherapy for patients with inoperable locally advanced pancreatic cancer," has been published in "Pancreas." Such paper refers the result of a collaborative clinical study for pancreatic cancer with Nagoya University Hospital. |
| 3) |
The paper, titled "Clinical and immunological evaluation of zoledoronate-activated Vγ9γδ T-cell-based immunotherapy for patients with multiple myeloma," has been published in "Experimental Hematology." This paper refers the result of collaborative clinical study against multiple myeloma with Japanese Red Cross Medical Center. |
As a consequence of our above stated results of collaborative clinical studies/ basic study, academia around the world has started to recognize safety and efficacy of the Immuno-Cell Therapy, and we believe in the value of our continuous R&D activities to contribute dissemination of the Immuno-Cell Therapy to the public and academia.
In closing, we thank all of our shareholders for commitment and support to MEDINET. We, our management and all employees, will continuously make every effort to accomplish our mission, and keep developing future-generation technologies of Immuno-Cell Therapy. As the objective of business activity in this year, we will keep profit-making activities, and will establish solid business platform for further business expansion. We sincerely look forward to your continuous support and commitment in our business activities.
